Learn more about the discovery and approval of Kisqali®
Astex Pharmaceuticals and Otsuka announce results of the Phase 3 ASCERTAIN study of oral cedazuridine and decitabine fixed-dose combination (ASTX727) in subjects with MDS and CMML
Actively building an oncology and CNS pipeline using a science-driven, open innovation approach
We’re a member of the Otsuka group of companies
Employment opportunities at our headquarters in UK and USA
